We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Flow Cytometric Assay Evaluated for Heparin-Induced Thrombocytopenia

By LabMedica International staff writers
Posted on 05 Jul 2016
Print article
Image: The FACSCalibur flow cytometer modular analyzer (Photo courtesy of BD Biosciences).
Image: The FACSCalibur flow cytometer modular analyzer (Photo courtesy of BD Biosciences).
Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenia associated with heparin therapy and the diagnosis consists of a combination of pretest probability and laboratory testing.

The routinely available laboratory antigen binding assays for the detection of specific antibodies have a low HIT-positive predictive value; therefore, to exclude false-positive results, one of the functional assays should be performed. Functional assays evaluate the ability of heparin/platelet factor 4 (PF4) antibodies to activate the platelets.

Scientists at the University Medical Centre Ljubljana (Slovenia) investigated sera from adult patients, in which HIT was suspected, for the presence of HIT antibodies, using an immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) as the laboratory standard practice. After they set up the functional assay, 41 ELISA-positive serum samples were collected randomly for further testing.

The team tested the sera using an IgG-specific ELISA Kit (GTI Diagnostics, Inc., Waukesha, WI, USA). Platelet-activating antibodies were detected with a functional flow cytometric assay and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). A functional heparin-induced platelet aggregation assay (HIPA) was also performed. Each test included diluted serum from the HIT patients as weak positive controls and serum from healthy donors as negative controls. To set up the cutoff of the flow cytometric assay, they analyzed a total of 100 samples, 25 HIT-positive and HIT-negative sera, each tested with different donor platelets.

The scientists found that of 41 ELISA positive serum samples, 14 were positive and 20 were negative by both flow cytometer and HIPA. Three other samples were discrepant between two assays: they were HIPA-positive and were negative with the flow cytometric assay. Conversely, four samples were flow cytometer positive and HIPA-negative. The samples included in this comparison were sera with detected anti-heparin/PF4 IgG antibodies with an OD greater than 0.4. The diagnostic specificity of the flow cytometric assay was calculated based on HIPA results and was 83%.

The authors concluded that performing this functional test after the screening assay could significantly improve the specificity of HIT testing as heparin/PF4 antibodies are often not clinically significant. The study was published in the June 2016 edition of the International Journal of Laboratory Hematology.

Related Links:
University Medical Centre Ljubljana
GTI Diagnostics
Becton Dickinson
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.